Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.35
-$0.44-55.73%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.49M | 8.27M | 7.98M | 8.18M | 7.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.20M | 22.93M | 27.36M | 29.41M | 30.80M |
| Operating Income | -20.20M | -22.93M | -27.36M | -29.41M | -30.80M |
| Income Before Tax | -19.85M | -22.74M | -27.09M | -28.90M | -29.90M |
| Income Tax Expenses | 18.90K | 20.70K | 17.90K | 17.30K | 19.50K |
| Earnings from Continuing Operations | -19.86 | -22.76 | -27.11 | -28.92 | -29.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.86M | -22.76M | -27.11M | -28.92M | -29.92M |
| EBIT | -20.20M | -22.93M | -27.36M | -29.41M | -30.80M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -6.74 | -9.25 | -13.10 | -15.81 | -18.14 |
| Normalized Basic EPS | -4.21 | -5.78 | -8.18 | -9.88 | -11.33 |
| EPS Diluted | -6.74 | -9.25 | -13.10 | -15.81 | -18.14 |
| Normalized Diluted EPS | -4.21 | -5.78 | -8.18 | -9.88 | -11.33 |
| Average Basic Shares Outstanding | 14.50M | 10.60M | 8.65M | 7.69M | 6.75M |
| Average Diluted Shares Outstanding | 14.50M | 10.60M | 8.65M | 7.69M | 6.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |